title: Sulforaphane protects against sodium valproate-induced acute liver injury.
abstract: Drug-induced hepatotoxicity is one of the most commonly encountered obstacles in the field of medical practice. Sodium valproate (VPA) is among many drugs with reported hepatotoxic effects. Sulforaphane (SFN) is a thiol compound found in wide abundance in cruciferous plants that has numerous reported therapeutic efficacies. The current investigation sheds light on the potential hepatoprotective effect of SFN against VPA-induced liver injury in rats. Twice daily VPA (700 mg/kg, i.p.) for 7 days induced significant biochemical alterations and hepatic histopathological damage. SFN (0.5 mg/kg, orally) for 7 days significantly boosted liver function biomarkers; it reduced serum alanine transaminase, aspartate aminotransferase, and alkaline phosphatase, and restored serum albumin concentration in a significant manner. Meanwhile, SFN significantly mitigated VPA-induced histopathological alterations. To highlight the mechanisms implicated in the observed hepatoprotective action, hepatic malondialdehyde and tumour necrosis factor α content significantly declined with concomitant increase in hepatic heme oxygenase-1 content and glutathione concentration with SFN treatment. In conclusion, SFN can significantly ameliorate VPA-induced hepatotoxicity and liver injury primarily by direct association between antioxidant and anti-inflammatory properties.
authors.affiliation: a Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
authors.forename: Entsar A
authors.initials: EA
authors.lastname: Nazmy
authors.affiliation: a Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
authors.forename: Omar A
authors.initials: OA
authors.lastname: El-Khouly
authors.affiliation: b Faculty of Medicine, Mansoura University, Mansoura, Egypt.
authors.forename: Hoda
authors.initials: H
authors.lastname: Atef
authors.affiliation: a Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
authors.forename: Eman
authors.initials: E
authors.lastname: Said
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000032:analysis; D001937:Brassica / Q000737:chemistry; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004827:Epilepsy / Q000188:drug therapy; D005978:Glutathione / Q000378:metabolism; D051547:Heme Oxygenase-1 / Q000378:metabolism; D006801:Humans; D017879:Isothiocyanates / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D064209:Phytochemicals / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013454:Sulfoxides; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D016588:Anticarcinogenic Agents; D000927:Anticonvulsants; D000975:Antioxidants; D015415:Biomarkers; D017879:Isothiocyanates; D064209:Phytochemicals; D013454:Sulfoxides; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D014635:Valproic Acid; D051547:Heme Oxygenase-1; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C016766:sulforaphane; D005978:Glutathione
keywords: TNFα; heme oxygenase-1; hème oxygénase 1; liver injury; lésions hépatiques; sodium valproate; sulforaphane; valproate de sodium